Elikya Therapeutics is a biotechnology start-up part of the Nexus of Landmark BioVentures. The company is developing new generation of Antibody Drug Conjugates (ADCs) in oncology using its proprietary and first-in-class toxic payloads. The company is a spin-off of the University Paris Saclay, France (UPS) and the Gustave Roussy Institute (IGR) in France. Through its academic founders, Elikya Therapeutics is leveraging more than 15 years of world recognized research. The team is also composed of seasoned team of biotech industrials with more than 35 years of experience in the biotech and pharma industry.
The company is currently is hosted at the incubator, Quest for Health (SEMIA) in Strasbourg, France.
Elikya Therapeutics is focused on the development of First-in-Class toxic payloads for ADC and intra-tumoral therapies with differentiated mechanism of action against cancer cells and tumoral micro-environment.

Elikya Therapeutics is part of the nexus of Landmark Bioventures. (www-landmarkbioventures.com)​

Elikya Therapeutics

Org chart

Teams

Offices

Elikya Therapeutics

Org chart

Teams

Offices

Related companies